Targets › CD30
9 programs from 6 companies in 17 trials: 15 Phase 1, 2 Phase 2; Oncology; next expected readout Apr 2027.
Receptor for TNFSF8/CD30L. May play a role in the regulation of cellular growth and transformation of activated lymphoblasts. Regulates gene expression through activation of NF-kappa-B. (UniProt, P28908)
Open in Phaseline: the race on CD30, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| UNC Lineberger Comprehensive Cancer Center | ATLCAR.CD30.CCR4 cells CD30-targeted CAR-T cell therapy | CD30 | Phase 2 | Peripheral T Cell Lymphoma; Hodgkin Lymphoma; Hodgkin Disease; Lymphoma | Feb 2028 |
| Tessa Therapeutics | Autologous CD30.CAR-T CD30-directed CAR-T cell therapy | CD30 | Phase 2 | Hodgkin Lymphoma, Adult; Anaplastic Large Cell Lymphoma; Classical Hodgkin Lymphoma | Mar 2036 |
| Baylor College of Medicine | C7R.CD30.CAR-EBVST cells Allogeneic CD30 chimeric antigen receptor (CAR) T cells with constitutive IL7R signaling d | CD30 | Phase 1 | Hodgkin's Lymphoma; Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type; CD30-Positive Diffuse Large B-Cell Lymphoma | Apr 2027 |
| Beijing Biotech | EB-CAR30-NK CD30-targeted allogeneic CAR-NK cells | CD30 | Phase 1 | B2 Thymoma | Jun 2027 |
| Ruijin Hospital | LCAR-HL30 CD30-targeted CAR-T cell therapy | CD30 | Phase 1 | Hodgkin's Lymphoma | Aug 2028 |
| Chinese PLA General Hospital | CD30-targeting CAR-T Cell Therapy Chimeric antigen receptor T cell therapy targeting CD30 | CD30 | Phase 1 | Lymphoma | Aug 2028 |
| Chinese PLA General Hospital | CART30 anti-CD30 CAR T cell therapy | CD30 | Phase 1 | Hodgkin's Lymphoma | Oct 2029 |
| Baylor College of Medicine | autologous CAR.CD30 EBV specific-CTLs CD30-targeted chimeric antigen receptor T cell therapy; EBV-specific CTLs engineered to ex | CD30 | Phase 1 | Hodgkin's Lymphoma | Oct 2033 |
| UNC Lineberger Comprehensive Cancer Center | ALTCAR.CD30 cells CD30-targeted CAR-T cells | CD30 | Phase 1 | Lymphoma | Nov 2039 |
Hodgkin's Lymphoma (4) Lymphoma (4) Hodgkin Lymphoma, Adult (1) Anaplastic Large Cell Lymphoma (1) Classical Hodgkin Lymphoma (1) Peripheral T Cell Lymphoma (1) Hodgkin Lymphoma (1) Hodgkin Disease (1) B2 Thymoma (1) Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type (1) CD30-Positive Diffuse Large B-Cell Lymphoma (1)
mixed (4), other (3), protein or peptide (1), small molecule (1)
Chinese PLA General Hospital (2) Baylor College of Medicine (2) UNC Lineberger Comprehensive Cancer Center (2) Tessa Therapeutics (1) Ruijin Hospital (1) Beijing Biotech (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.